E 64

Drug Profile

E 64

Latest Information Update: 10 Nov 2006

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Calpain inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Cataracts

Most Recent Events

  • 10 Nov 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
  • 10 Nov 2006 Discontinued - Preclinical for Cataracts in Germany (unspecified route)
  • 10 May 2000 A preclinical study has been added to the Eye Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top